Cardiac Arrhythmia Management

Introduction to Sick Sinus Syndrome

Sick sinus syndrome (SSS) is characterized by symptomatic bradycardia with or without bradycardia-dependent tachycardia, requiring symptom-rhythm correlation, either spontaneously or when drug-induced, where alternative therapy is lacking, as noted by the European Society of Cardiology and other authorities 1

A marked prolongation of sinus node recovery time (SNRT) (>3 seconds) suggests SSS as the cause of syncope, according to the European Society of Cardiology 2
Correlation of symptoms with bradyarrhythmia can be documented using ECG, ambulatory ECG monitoring (Holter), event recorder, or implantable loop recorder, as recommended by the American Academy of Family Physicians 3
A temporal relationship between tachycardia and bradycardia is crucial, with electrocardiographic evidence of both bradycardia and tachycardia required for diagnosis, as suggested by multiple studies 4, 5, 6
Extended monitoring, including 24-hour Holter monitoring, event monitoring, implantable loop recorder, and inpatient telemetry, is often necessary to capture the relationship between sinus arrhythmia and atrial fibrillation, with a Class IIb recommendation for electrophysiological studies (EPS) in selected patients 4, 5, 6

Discontinuing or reducing bradycardia-inducing medications and correcting electrolyte abnormalities can help manage bradyarrhythmia, according to the American Academy of Family Physicians 3
Treating underlying conditions, such as sleep apnea, is also important in managing bradyarrhythmia, as suggested by the American Academy of Family Physicians 3
The European Society of Cardiology recommends beta-blockers as first-line therapy for older patients (>70 years) with minimal symptoms, and also suggests beta-blockers or non-dihydropyridine calcium channel antagonists (with caution in hypotension or heart failure) 7

For patients with concomitant heart failure, digitalis or amiodarone may be considered, according to the European Society of Cardiology 7
The European Society of Cardiology recommends considering antiarrhythmic therapy primarily based on safety, with flecainide, propafenone, or sotalol as initial therapy for patients with minimal/no heart disease, and amiodarone for patients with heart disease 8
For symptomatic tachycardia component, the American College of Cardiology recommends beta-blockers as first-line treatment for adrenergically mediated sinus tachycardia, with consideration of combination therapy with beta-blocker plus Class IC agent in resistant cases 9

Pacemaker implantation is indicated when symptoms correlate with bradyarrhythmia, medical therapy is ineffective or contraindicated, as recommended by the American College of Cardiology 10
Dual-chamber rate-adaptive pacing (DDDR) is preferred over single-chamber pacing, as it is associated with a lower incidence of paroxysmal atrial fibrillation and reduces the need for reoperation, according to the American College of Cardiology and the European Society of Cardiology 10, 4, 11, 6

Regular assessment of symptom control, ECG monitoring to evaluate treatment efficacy, and adjustment of medications based on response are essential for effective management, as recommended by multiple authorities 9, 12, 13, 2
Regular device checks are recommended to ensure proper function, continued monitoring for development of atrial fibrillation, and adjustment of pacing parameters as needed, as recommended by the American College of Cardiology 10
Anticoagulation should be considered in patients with sinus arrhythmia and atrial fibrillation due to increased thromboembolic risk, as recommended by the American College of Cardiology and the European Heart Journal 10, 6

Athletes with sinus bradycardia often have a physiologic condition that does not require pacing, with normal resting heart rates of 40-50 bpm and nocturnal rates as low as 30 bpm, as noted by the American Academy of Family Physicians 3
For patients with vagally-mediated sinus arrhythmia, anticholinergic agents like disopyramide may be considered, while for adrenergically-mediated sinus arrhythmia, beta-blockers are first-line, as suggested by the American College of Cardiology 9
The combination of sinus arrhythmia and atrial fibrillation increases thromboembolic risk, with a 15.2% risk of systemic embolism in unpaced patients compared to 1.3% in age-matched controls, as reported in the European Heart Journal 6
Patients with sinus arrhythmia have a high incidence of developing atrial fibrillation, with 8.2% at initial diagnosis and increasing to 15.8% during follow-up, according to the European Heart Journal 6